HomeCompareSPPI vs YUM

SPPI vs YUM: Dividend Comparison 2026

SPPI yields 14.63% · YUM yields 1.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 YUM wins by $55.7K in total portfolio value· pulled ahead in Year 8
10 years
SPPI
SPPI
● Live price
14.63%
Share price
$1.03
Annual div
$0.15
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$52.2K
Annual income
$3,617.47
Full SPPI calculator →
YUM
YUM
● Live price
1.86%
Share price
$154.59
Annual div
$2.88
5Y div CAGR
51.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$107.9K
Annual income
$40,443.52
Full YUM calculator →

Portfolio growth — SPPI vs YUM

📍 YUM pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSPPIYUM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SPPI + YUM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SPPI pays
YUM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SPPI
Annual income on $10K today (after 15% tax)
$1,243.90/yr
After 10yr DRIP, annual income (after tax)
$3,074.85/yr
YUM
Annual income on $10K today (after 15% tax)
$158.35/yr
After 10yr DRIP, annual income (after tax)
$34,376.99/yr
At 15% tax rate, YUM beats the other by $31,302.14/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SPPI + YUM for your $10,000?

SPPI: 50%YUM: 50%
100% YUM50/50100% SPPI
Portfolio after 10yr
$80.1K
Annual income
$22,030.49/yr
Blended yield
27.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on YUM right now

SPPI
Analyst Ratings
6
Buy
7
Hold
1
Sell
Consensus: Hold
Price Target
$0.75
-26.8% upside vs current
Range: $0.75 — $0.75
Altman Z
-14.1
Piotroski
3/9
YUM
Analyst Ratings
18
Buy
30
Hold
3
Sell
Consensus: Hold
Price Target
$173.15
+12.0% upside vs current
Range: $158.00 — $190.00
Altman Z
2.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SPPI buys
0
YUM buys
0
No recent congressional trades found for SPPI or YUM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSPPIYUM
Forward yield14.63%1.86%
Annual dividend / share$0.15$2.88
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.4%
Portfolio after 10y$52.2K$107.9K
Annual income after 10y$3,617.47$40,443.52
Total dividends collected$24.9K$81.2K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusHoldHold
Analyst price target$0.75$173.15

Year-by-year: SPPI vs YUM ($10,000, DRIP)

YearSPPI PortfolioSPPI Income/yrYUM PortfolioYUM Income/yrGap
1$12,163$1,463.41$10,982$282.06+$1.2KSPPI
2$14,678$1,663.56$12,189$438.29+$2.5KSPPI
3$17,582$1,876.20$13,731$688.32+$3.9KSPPI
4$20,913$2,100.33$15,789$1,097.12+$5.1KSPPI
5$24,712$2,334.81$18,679$1,785.08+$6.0KSPPI
6$29,020$2,578.43$22,975$2,988.18+$6.0KSPPI
7$33,881$2,829.86$29,784$5,200.49+$4.1KSPPI
8← crossover$39,341$3,087.76$41,408$9,539.16$2.1KYUM
9$45,446$3,350.75$63,071$18,765.27$17.6KYUM
10$52,244$3,617.47$107,930$40,443.52$55.7KYUM

SPPI vs YUM: Complete Analysis 2026

SPPIStock

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Boston, Massachusetts.

Full SPPI Calculator →

YUMConsumer Discretionary

YUM! Brands, Inc., together with its subsidiaries, develops, operates, and franchises quick service restaurants worldwide. It operates through four segments: the KFC Division, the Taco Bell Division, the Pizza Hut Division, and the Habit Burger Grill Division. The company operates restaurants under the KFC, Pizza Hut, Taco Bell, and The Habit Burger Grill brands, which specialize in chicken, pizza, made-to-order chargrilled burgers, sandwiches, Mexican-style food categories, and other food products. As of December 31, 2021, it had 26,934 KFC units; 18,381 Pizza Hut units; 7,791 Taco Bell units; and 318 The Habit Burger Grill units in approximately 157 countries and territories. The company was formerly known as TRICON Global Restaurants, Inc. and changed its name to YUM! Brands, Inc. in May 2002. YUM! Brands, Inc. was incorporated in 1997 and is headquartered in Louisville, Kentucky.

Full YUM Calculator →
📬

Get this SPPI vs YUM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SPPI vs SCHDSPPI vs JEPISPPI vs OSPPI vs KOSPPI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.